These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 19944395)
1. Challenging the dogma of high target doses in the treatment of heart failure: is more always better? Follath F Arch Cardiovasc Dis; 2009 Nov; 102(11):785-9. PubMed ID: 19944395 [TBL] [Abstract][Full Text] [Related]
2. A review of heart failure management in the elderly population. Cheng JW; Nayar M Am J Geriatr Pharmacother; 2009 Oct; 7(5):233-49. PubMed ID: 19948300 [TBL] [Abstract][Full Text] [Related]
3. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692 [TBL] [Abstract][Full Text] [Related]
4. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Heywood JT; Fonarow GC; Yancy CW; Albert NM; Curtis AB; Gheorghiade M; Inge PJ; McBride ML; Mehra MR; O'Connor CM; Reynolds D; Walsh MN Circ Heart Fail; 2010 Sep; 3(5):596-605. PubMed ID: 20634483 [TBL] [Abstract][Full Text] [Related]
5. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Remme WJ; McMurray JJ; Hobbs FD; Cohen-Solal A; Lopez-Sendon J; Boccanelli A; Zannad F; Rauch B; Keukelaar K; Macarie C; Ruzyllo W; Cline C; Eur Heart J; 2008 Jul; 29(14):1739-52. PubMed ID: 18506054 [TBL] [Abstract][Full Text] [Related]
6. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy. Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C; Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142 [TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
8. [Addition of beta blockers in chronic heart failure]. Missault LH; van Veldhuisen DJ Ned Tijdschr Geneeskd; 2000 Sep; 144(40):1905-10. PubMed ID: 11045137 [TBL] [Abstract][Full Text] [Related]
9. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. Willenheimer R; Erdmann E; Follath F; Krum H; Ponikowski P; Silke B; Van Veldhuisen DJ; Van De Ven L; Verkenne P; Lechat P; Eur J Heart Fail; 2004 Jun; 6(4):493-500. PubMed ID: 15182776 [TBL] [Abstract][Full Text] [Related]
10. How well are chronic heart failure patients being managed? Fonarow GC Rev Cardiovasc Med; 2006; 7 Suppl 1():S3-11. PubMed ID: 16955055 [TBL] [Abstract][Full Text] [Related]
11. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F; Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945 [TBL] [Abstract][Full Text] [Related]
12. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005]. Fabbri G; Gorini M; Maggioni AP; Di Lenarda A; G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354 [TBL] [Abstract][Full Text] [Related]
13. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Fonarow GC; Abraham WT; Albert NM; Gattis WA; Gheorghiade M; Greenberg B; O'Connor CM; Yancy CW; Young J Am Heart J; 2004 Jul; 148(1):43-51. PubMed ID: 15215791 [TBL] [Abstract][Full Text] [Related]
14. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction. Azadpour M; Lamas GA Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434 [TBL] [Abstract][Full Text] [Related]
15. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Dulin BR; Krum H Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210 [TBL] [Abstract][Full Text] [Related]
16. A survey of outpatient management of elderly heart failure patients in Poland-treatment patterns. Rywik TM; Rywik SL; Korewicki J; Broda G; Sarnecka A; Drewla J Int J Cardiol; 2004 Jun; 95(2-3):177-84. PubMed ID: 15193817 [TBL] [Abstract][Full Text] [Related]
17. [Pharmacological therapy of chronic heart failure in the elderly]. Sabbadini G; Di Lenarda A; Metra M; Nodari S; Moretti M; Brentana L; Dei Cas L; Sinagra G Ital Heart J; 2004 Dec; 5 Suppl 10():37S-51S. PubMed ID: 15712511 [TBL] [Abstract][Full Text] [Related]
18. Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice--results from a cluster-randomized controlled trial of implementation of a clinical practice guideline. Peters-Klimm F; Müller-Tasch T; Remppis A; Szecsenyi J; Schellberg D J Eval Clin Pract; 2008 Oct; 14(5):823-9. PubMed ID: 19018915 [TBL] [Abstract][Full Text] [Related]
19. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic]. Pölzl G; Gouya G; Hügel H; Frick M; Ulmer H; Pachinger O Wien Klin Wochenschr; 2002 Oct; 114(19-20):833-9. PubMed ID: 12503474 [TBL] [Abstract][Full Text] [Related]
20. What does ATLAS really tell us about "high" dose angiotensin-converting enzyme inhibition in heart failure? Nicklas JM; Cohn JN; Pitt B J Card Fail; 2000 Jun; 6(2):165-8. PubMed ID: 10908091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]